NCT04183712 2024-10-16
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05865132 2023-05-18
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT04880811 2021-07-13
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Peking University
Phase 2 Unknown
NCT03940976 2019-06-11
Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
Peking University
Phase 2 Unknown
NCT02353936 2019-02-11
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Yonsei University
Phase 2 Unknown
NCT01919879 2018-05-08
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT02274012 2017-03-14
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Columbia University
Phase 2 Withdrawn